Related Experiment Video
Updated: Apr 5, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.8K
Direct oral anticoagulants (DOACs)
Sara Vazquez1, Matthew T Rondina2
1University Healthcare Thrombosis Service, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
Vascular Medicine (London, England)
|August 20, 2015
Summary
Newer blood thinners, direct oral anticoagulants (DOACs), offer potential benefits over warfarin. Healthcare providers guide patients on DOAC suitability, medication adjustments, surgical plans, and managing bleeding risks.
Area of Science:
- Pharmacology
- Cardiology
- Internal Medicine
Background:
- Warfarin has been a long-standing anticoagulant, but requires frequent monitoring.
- Direct oral anticoagulants (DOACs) represent a newer class of blood-thinning medications.
- DOACs may offer advantages in efficacy and safety profiles compared to warfarin.
Purpose of the Study:
- To inform healthcare providers and patients about the considerations for choosing direct oral anticoagulants (DOACs).
- To highlight the potential advantages of DOACs over traditional anticoagulants like warfarin.
- To emphasize the importance of patient-provider communication regarding DOAC therapy.
Main Methods:
- This is a summary of current knowledge and clinical considerations regarding DOACs.
- It involves evaluating factors influencing the choice between DOACs and warfarin.
- Discussion includes management strategies for patients on DOACs.
Main Results:
- DOACs present a viable alternative to warfarin for anticoagulation.
- Individual patient factors are crucial in determining the optimal anticoagulant choice.
- Careful management is needed for medication changes, perioperative care, and monitoring for bleeding.
Conclusions:
- Direct oral anticoagulants (DOACs) are an important advancement in anticoagulant therapy.
- Shared decision-making between patients and healthcare providers is essential for selecting appropriate anticoagulants.
- Proactive management of DOAC therapy, including surgical planning and bleeding risk assessment, is critical for patient safety.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
01:29Venous Thrombosis III: Interprofessional Care
466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:23Oral Drug Delivery Systems: Introduction
214
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
214
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K